Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ocular Therapeutix (OCUL) Misses Q4 EPS by $1.04, Revenues Miss
March 11, 2021 4:04 PM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($1.21), $1.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.35 million versus the consensus estimate of $9.76 million.
The fourth quarter marked considerable commercial, clinical and regulatory progress for the Company, said Antony Mattessich, President... More
